Literature DB >> 23766485

Molecular and phenotypic evidence for the spread of three major methicillin-resistant Staphylococcus aureus clones associated with two characteristic antimicrobial resistance profiles in China.

Hang Cheng1, Wenchang Yuan, Fangyin Zeng, Qiwen Hu, Weilong Shang, Dahai Tang, Wencheng Xue, Jianfeng Fu, Jie Liu, Nan Liu, Junmin Zhu, Jie Yang, Zhen Hu, Jizhen Yuan, Xia Zhang, Shu Li, Zhijin Chen, Xiaomei Hu, Xiancai Rao.   

Abstract

OBJECTIVES: The distribution of methicillin-resistant Staphylococcus aureus (MRSA) clones is dynamic and geographically unique. To understand the changing epidemiology of MRSA infections in China, we performed a prospective, multicity surveillance study with molecular typing and phenotypic analysis to determine the association of major prevalent clones with their antimicrobial resistance profiles.
METHODS: A total of 517 S. aureus isolates collected between January 2009 and March 2012 from six cities in China were subjected to antibiogram analysis and molecular typing, including staphylococcal cassette chromosome mec typing, multilocus sequence typing, staphylococcal protein A gene typing and PFGE typing.
RESULTS: Among the isolates collected, 309 were characterized as MRSA, with a prevalence of 59.8%. Three major clones were found to be prevalent in China: ST239-MRSA-III-t030, ST239-MRSA-III-t037 and ST5-MRSA-II-t002. These three clones were associated with two characteristic resistance profiles, namely, gentamicin/ciprofloxacin/rifampicin/levofloxacin for the first clone and gentamicin/ciprofloxacin/clindamycin/erythromycin/tetracycline/levofloxacin/trimethoprim/sulfamethoxazole for the latter two. Several geographically unique minor clones were also identified.
CONCLUSIONS: The predominant MRSA clones in China were associated with characteristic antimicrobial resistance profiles. Antibiotics for treating patients with MRSA infections can be selected based on the strain typing data.

Entities:  

Keywords:  antibiogram analysis; clonal complexes; drug resistance profiles; molecular typing

Mesh:

Substances:

Year:  2013        PMID: 23766485     DOI: 10.1093/jac/dkt213

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  24 in total

1.  Prevalence of Enterotoxin Genes and spa Genotypes of Methicillin-resistant Staphylococcus aureus from a Tertiary Care Hospital in China.

Authors:  Yanmeng Li; Ruike Zhao; Xianfeng Zhang; Qingzhen Han; Xuefeng Qian; Guohao Gu; Jinfang Shi; Jie Xu
Journal:  J Clin Diagn Res       Date:  2015-05-01

2.  Panton-Valentine leukocidin (PVL)-positive health care-associated methicillin-resistant Staphylococcus aureus isolates are associated with skin and soft tissue infections and colonized mainly by infective PVL-encoding bacteriophages.

Authors:  Qiwen Hu; Hang Cheng; Wenchang Yuan; Fangyin Zeng; Weilong Shang; Dahai Tang; Wencheng Xue; Jianfeng Fu; Renjie Zhou; Junmin Zhu; Jie Yang; Zhen Hu; Jizhen Yuan; Xia Zhang; Qing Rao; Shu Li; Zhijin Chen; Xiaomei Hu; Xingan Wu; Xiancai Rao
Journal:  J Clin Microbiol       Date:  2014-10-22       Impact factor: 5.948

3.  Antimicrobial Resistance Patterns in Methicillin-Resistant Staphylococcus aureus from Patients Hospitalized during 2015-2017 in Hospitals in Poland.

Authors:  Barbara Kot; Kamila Wierzchowska; Małgorzata Piechota; Agata Grużewska
Journal:  Med Princ Pract       Date:  2019-07-01       Impact factor: 1.927

4.  Decreased Incidence of Methicillin-Resistant Staphylococcus aureus Bacteremia in Intensive Care Units: a 10-Year Clinical, Microbiological, and Genotypic Analysis in a Tertiary Hospital.

Authors:  Haein Kim; Eun Sil Kim; Seung Cheol Lee; Eunmi Yang; Hee Sueng Kim; Heungsup Sung; Mi-Na Kim; Jiwon Jung; Min Jae Kim; Sung-Han Kim; Sang-Oh Lee; Sang-Ho Choi; Jun Hee Woo; Yang Soo Kim; Yong Pil Chong
Journal:  Antimicrob Agents Chemother       Date:  2020-09-21       Impact factor: 5.191

5.  Antibiotic Resistance Patterns and Molecular Characterization of Methicillin-Resistant Staphylococcus aureus in Clinical Settings in Rwanda.

Authors:  Florence Masaisa; Etienne Kayigi; Jeremiah Seni; Freddie Bwanga; Claude Mambo Muvunyi
Journal:  Am J Trop Med Hyg       Date:  2018-11       Impact factor: 2.345

6.  Characterization of Staphylococcus aureus from distinct geographic locations in China: an increasing prevalence of spa-t030 and SCCmec type III.

Authors:  Yong Chen; Zhengxiang Liu; Libo Duo; Jie Xiong; Yanwen Gong; Jiyong Yang; Zhanke Wang; Xuqin Wu; Zhongyi Lu; Xiangzhao Meng; Jingya Zhao; Changjian Zhang; Fang Wang; Yulong Zhang; Mengqiang Zhang; Li Han
Journal:  PLoS One       Date:  2014-04-24       Impact factor: 3.240

7.  An improved MLVF method and its comparison with traditional MLVF, spa typing, MLST/SCCmec and PFGE for the typing of methicillin-resistant Staphylococcus aureus.

Authors:  Xue-Fei Du; Meng Xiao; Hong-Yan Liang; Zhe Sun; Yue-Hong Jiang; Guo-Yu Chen; Xiao-Yu Meng; Gui-Ling Zou; Li Zhang; Ya-Li Liu; Hui Zhang; Hong-Li Sun; Xiao-Feng Jiang; Ying-Chun Xu
Journal:  Int J Mol Sci       Date:  2014-01-08       Impact factor: 5.923

8.  Dissemination of fusidic acid resistance among Staphylococcus aureus clinical isolates.

Authors:  Fangyou Yu; Yunling Liu; Chaohui Lu; Jinnan Lv; Xiuqin Qi; Yu Ding; Dan Li; Xiaoying Huang; Longhua Hu; Liangxing Wang
Journal:  BMC Microbiol       Date:  2015-10-13       Impact factor: 3.605

9.  Clinical characteristics, virulence factors and molecular typing of methicillin-resistant Staphylococcus aureus infections in Shenzhen City, China.

Authors:  L Hu; Y Li; Y Lu; J D Klena; Y Qiu; Y Lin; M Jiang; X Shi; L Chen; X Liu; H Ma; J Cheng; S Wu; B Kan; Q Hu
Journal:  Epidemiol Infect       Date:  2016-07-22       Impact factor: 4.434

10.  Complete Genome Sequence of Staphylococcus aureus XN108, an ST239-MRSA-SCCmec III Strain with Intermediate Vancomycin Resistance Isolated in Mainland China.

Authors:  Xia Zhang; Xiaomeng Xu; Wenchang Yuan; Qiwen Hu; Weilong Shang; Xiaomei Hu; Yigang Tong; Xiancai Rao
Journal:  Genome Announc       Date:  2014-07-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.